KRAS and cancer: A variant of MRTX849, MRTX1133, shown in Figure 6C, has been recently synthesized in which a bicyclo piperazine ring that is positively charged replaced the fluoroacryl group, allowing for this moiety to make favorable electrostatic contact with the Asp 12 residue of G12D-K-RAS-p21-GDP with a binding constant in the low nanomolar range [33,36], making this drug an excellent candidate for the treatment of G12D-K-RAS-p21-induced cancers.